Pharvaris N.V.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Pharvaris N.V. now
Current reporting with the operating signal separated from the noise.
Pharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
The story matters when it changes Pharvaris N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
The story matters when it changes Pharvaris N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Pharvaris N.V.
The story matters when it changes Pharvaris N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Cantor Fitzgerald Initiates Coverage of Pharvaris N.V. (PHVS) with Overweight Recommendation
The story matters when it changes Pharvaris N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest PHVS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Pharvaris N.V., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →